|
|
Article: Par Pharmaceutical acquires five products from Bristol-Myers Squibb.
- Article from:
- Biotech Week
- Article date:
- April 10, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 APR 10 - (NewsRx.com & NewsRx.net) -- Par Pharmaceutical, Inc., a subsidiary of Pharmaceutical Resources, Inc., (PRX) has acquired the U.S. rights to five products from Bristol-Myers Squibb.
The products include the antihypertensives Capoten and Capozide, the cholesterol-lowering medications Questran and Questran Light, and Sumycin, an antibiotic.
"Acquiring these well-respected products expands our product portfolio and immediately enhances our company's profitability," said Scott Tarriff, president and chief executive officer of Par Pharmaceutical.
Based on current market information, these products are expected to generate annual sales ...